Objective: The aim of this report is to evaluate whether cortexin provides any protective activity against ototoxicity of cisplatin.

Materials And Methods: The study was performed on 30 healthy adult Wistar Albino rats, and rats were randomly divided into three groups of ten. Group I (Control group) was given intraperitoneal (ip) saline solution 1 mL/day. Group II (Cisplatin group) was given ip cisplatin for 2 days at doses of 10 mg/kg. Group III (Cisplatin + Cortexin group) was given ip cisplatin for 2 days at same doses with ip cortexin 2 mg/day for 7 days. Before and on the fourth day of the study, all subjects underwent auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAE) tests. At the end of fourth day, half of the subjects in all three groups were decapitated, and their cochlea were removed for histopathologic examination. On the eighth day, tests of the remaining subjects and histopathological examinations were repeated.

Results: ABR tests on the fourth and eighth days showed elevations in the mean hearing thresholds of Groups II and III compared to Group I (p < 0.05). DPOAE tests revealed a loss in emission values on the fourth and eighth days of the study compared to the baseline in Groups II and III. Comparison of Groups II with III showed that emission loss was higher in Group II at both time points, and the difference was more pronounced on the eighth day. Histopathological findings supported these tests.

Conclusion: Cortexin provide protective activity against cisplatin-induced ototoxicity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354512PMC
http://dx.doi.org/10.5152/iao.2017.3825DOI Listing

Publication Analysis

Top Keywords

group cisplatin
12
groups iii
12
cisplatin-induced ototoxicity
8
protective activity
8
three groups
8
group
8
cisplatin days
8
days doses
8
fourth day
8
dpoae tests
8

Similar Publications

Conventional chemoradiation versus accelerated chemoradiation: A prospective study in oropharyngeal cancer.

Natl J Maxillofac Surg

November 2024

Department of Head and Neck (Oral and Maxillofacial Surgery), Kalyan Singh Super Speciality Cancer Institute, Lucknow, Uttar Pradesh, India.

Background: Squamous-cell carcinoma of the head and neck is predominantly a loco regional disease, and the primary treatment methods are surgery and radiotherapy. For patients with locally-regionally advanced oropharyngeal cancer, concurrent chemoradiotherapy is the standard treatment.

Material And Method: The aim and objectives of study were a) to compare locoregional response in two arms, b) to compare acute and chronic treatment-related toxicities in the two arms, and c) to compare the quality of life.

View Article and Find Full Text PDF

Chemotherapy is an effective treatment for gastric cancer. However, many patients develop resistance to chemotherapeutic agents during clinical treatment. LncRNA CCAT1 has recently been shown to influence cellular resistance to specific chemotherapeutic drugs, but its role in gastric cancer remains underexplored.

View Article and Find Full Text PDF

Background: This network meta-analysis (NMA) aims to provide evidence-based guidance for selecting the second-line chemotherapy for biliary tract cancer (BTC).

Methods: A comprehensive literature search was conducted on PubMed, Cochrane, and EMBASE through July 2024. Inclusion criteria involved: (1) patients underwent second-line chemotherapy following platinum-based first-line therapy, (2) intervention/comparator groups consisted of various chemotherapeutic agents, and (3) outcomes measured as hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS) in randomized controlled trials (RCTs) and cohort studies.

View Article and Find Full Text PDF

The effectiveness and safety of combining anlotinib with gemcitabine and cisplatin in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) have not been definitively established. This research seeks to investigate the potential benefits and risks of utilizing this combination therapy in the first-line management of R/M NPC. The research involved 22 individuals diagnosed with R/M NPC and who had not undergone any previous treatment.

View Article and Find Full Text PDF

Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable (T4) esophageal squamous cell carcinoma (ESCC), but the prognosis is poor. Borderline resectable (T3br) ESCC has been discussed, but its clinical features and appropriate treatment are unclear. The effects of docetaxel plus cisplatin and 5-fluorouracil (DCF) therapy and subsequent surgery for potentially unresectable ESCC remain controversial.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!